[ad_1]
UK regulators have advised people with a “significant” history of allergic reactions not to take the Pfizer-BioNTech vaccine against COVID-19.
The call comes after two people had side effects on Tuesday, said Stephen Powis, medical director of the National Health Service (NHS), according to DPA and AFP, Agerpres reports.
Powis said such advice from the UK Medicines and Medicines Regulatory Agency (MHRA) is standard practice.
The UK was the first country to authorize the vaccine and launched a mass vaccination campaign on Tuesday, targeting caregivers in care facilities and the elderly.
“Two people with severe allergic reactions have reacted badly,” said Stephen Powis, medical director of the National Health Service (NHS). “They are both recovering well,” he said.
“As is customary with new vaccines, the MHRA has recommended that people with a significant history of allergic reactions not receive the vaccine as a precautionary measure, after two of those people responded negatively yesterday,” he said. these two people are “recovering well.”
Both people are prone to allergies, which makes them get adrenaline pumping all the time.
Therefore, the UK Medicines and Medicines Regulatory Agency (MHRA) has issued a recommendation not to vaccinate ‘persons with a significant history of allergic reactions to vaccines, medicines or foods (such as anaphylactic reactions or those for which recommends self-injecting adrenaline).
Nurses and doctors in the UK began administering the vaccine developed by German pharmaceutical company BioNTech and its US partner Pfizer on Tuesday. Residents of care facilities, as well as their caregivers, are the first to receive this vaccine, which is given in two doses every 21 days.
Initially, approximately 800,000 doses of the Pfizer-BioNTech vaccine will be administered out of the 40 million ordered by the government.
Despite the speed with which this vaccine is being launched, “we have not slowed it down” for sure, Pfizer chief Albert Bourla of Geneva said at an online roundtable Tuesday.
This vaccine relies on the genetic code of the SARS-CoV-2 virus to “train” the body’s immune system to create antibodies against it.
However, the Pfizer-BioNTec vaccine involves severe transport and storage restrictions and measures. Unlike its counterparts from the American company Moderna and Oxford / AstraZeneca, this vaccine comes with strict specifications in terms of storage and transportation.
According to AFP, the Food and Drug Administration (FDA) vaccine committee will meet on Thursday to consider BioNTech / Pfizer’s application for approval of its coronavirus vaccine.
